AchE Inhibitor and Insulin

University of Miami

Status and phase: Completed; Phase 1

Conditions: Diabetes Mellitus

Treatments: Drug: Pyridostigmine

Study type: Interventional

Funder types: Other

Identifiers

NCT03063515

20161065

Details and patient eligibility

About

The investigator will examine the effect of a single dose of pyridostigmine, AchE inhibitor on insulin secretion in healthy subjects. Each subject will undergo an intravenous glucose tolerance test (IVGTT) where IV glucose will be administered and the glucose excursion and insulin secretion response will be evaluated by measuring insulin and glucose at different time points. The test will be carried out twice, once without and once with the administration of a single dose of Pyridostigmine on two separate days. The investigator hypothesizes that inhibiting AChE will potentiate insulin secretion.

Enrollment: 12 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• 18 years and older

Exclusion criteria

• BMI >30 Kg/m2
• fasting glucose >100
• Glycohemoglobin (Hemoglobin A1C) 5.7% or more
• History of asthma
• Use of medications that may interfere with glucose metabolism

Trial design

Primary purpose: Basic Science

Allocation: Non-Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

12 participants in 2 patient groups

IVGTT without pyridostigmine

No Intervention group

Description:

An intravenous glucose tolerance test (IVGTT) will be performed without any medication for baseline comparison.

IVGTT with pyridostigmine

Active Comparator group

Description:

An IVGTT will be performed 2 hours after taking one single dose of pyridostigmine 60 mg

Treatment:

Drug: Pyridostigmine